SLC5A2 and type 2 diabetes mellitus: Reasons for the discrepancy between the SGLT2 inhibitor CVOTs and preclinical studies could stem from the majority of preclinical data being performed in nondiabetic animals, despite some evidence of benefit in animals with T2DM.